419Combined anti-VEGF, anti-CTLA4 and anti-PDL1 treatment induces strong immune responses in patients with cholangiocarcinoma: results from a clinical trial/in depth correlative studies and mouse studiesdoi:10.1136/jitc-2022-SITC2022.0419Background The addition of durvalumab (anti-PD-L1) to ...
4. Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600mutation-positive melanoma (IMspire150): primary analysis ...
2. Anti-PD-1 therapy and other checkpoint inhibitors are approved for the treatment of 14 cancer types, making around 39%3of all cancer patients eligible for checkpoint therapy. Unfortunately, only approximately 11%3of all cancer patients benefit from anti-PD-1 therapies. Yet, among patients...
The advent of immune checkpoint inhibitors (ICIs), specifically of antibodies targeting the programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathways, has revolutionized treatment for non-small cell lung cancer (NSCLC)1,2,3,4,5. PD-L1 immunohistochemical expression is cur...
After two weeks, tumors bearing mice were intraperitoneally (ip) treated with murine anti-PD-1 [RMP1–14] (5 mg/kg, twice week for 2 weeks), Pep R (2 mg/kg, 5 days per week for 2 weeks), or both agents.The results indicate that the combined treatment, Pep R plus ...
Significantly, PD-L1 expression may be influenced by the type of chemotherapy and the response to treatment, which in return will influence the efficacy of an anti-PD-(L)1 combination therapy [29,30,31]. Preclinical studies have provided supporting evidence for combining anti-PD-(L)1 therapy...
The CDK7/MYC/PD-L1 signature and infiltrating T cell status collectively stratified NSCLC patients into different risk groups. Conclusion These data suggest that the combined CDK7 inhibitor THZ1 and antiPD-1 therapy can be an effective treatment in NSCLC....
these agents alone. In this review article, we summarized several anti-PD-1/PD-L1 agents licensed for NSCLC treatment, with a focus on predictive biomarkers and companion diagnostic assays for identification of NSCLC patients for immunotherapy anti-PD-1/PDL1 antibodies. Of a great interest, ...
We report a case of a documented psoriasis flare with anti-PD-1 treatment for lung cancer.关键词: Keywords immunotherapy autoimmune disease psoriasis flare DOI: 10.1097/CJI.0000000000000121 被引量: 7 年份: 2016 收藏 引用 批量引用 报错 分享 全部来源 求助全文 全文购买 国家科技图书文献中心 (权威...
The function of partially exhausted CD8 + T cells could be partially rescued by immune checkpoint blockers, such as anti-PD1 or anti-PDL1 antibodies, which is currently one of the treatment strategies for cancer [7]. Recent studies suggest that several key genes participate in CD8 +...